nach oben

Current Rheumatology Reports

Erschienen in:

01.06.2012 | INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment

verfasst von: Tsuneyo Mimori, Ran Nakashima, Yuji Hosono

Erschienen in: Current Rheumatology Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Interstitial lung disease (ILD) is the most frequent organ involvement (found in nearly half) of myositis patients, but it reveals various clinical courses and therapeutic responsiveness according to clinical and serological subsets. Autoantibodies, as well as imaging and histopathological studies, are useful for the classification of ILD in myositis and provide useful information for predicting prognosis and determining treatment. Antisynthetase antibodies are correlated with chronic and recurrent ILD, whereas anti-CADM-140 (MDA5/IFIH1) antibodies are a marker of acute progressive ILD in clinically amyopathic dermatomyositis. Serum KL-6, SP-D, and ferritin are useful biomarkers for monitoring the activity and severity of ILD. Regarding treatment, glucocorticoids are the first-line drug, but additional immunomodulating drugs are also used in refractory patients. Cyclophosphamide and calcineurin inhibitors (cyclosporine and tacrolimus) appear to be the key drugs in the treatment of refractory myositis–ILD. Rituximab may become another candidate if these drugs are not effective.

Nakashima R, Mimori T. Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies. Int J Clin Rheumatol. 2010;5:523–36.CrossRef

• Saketkoo LA, Ascherman DP, Cottin V, et al. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev. 2010;6:108–19. This is a good review of ILD in IIM focusing on the pathogenesis, clinical manifestation, diagnosis and disease monitoring, and therapeutics.PubMedCrossRef

• Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies. What progress has been made in the past 35 years? Chest. 2010;138:1464–74. This is a good review of ILD in IIM focusing on pathogenesis, diagnosis, and current therapeutic approaches.PubMedCrossRef

• Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol. 2010;22:633–8. This is a good review describing recent findings regarding ILD in IIM, focusing on the phenotypes of ILD, autoantibodies, pathogenesis, and treatment.PubMedCrossRef

Frazier AR, Miller RD. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest. 1974;65:403–7.PubMedCrossRef

Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614–22.PubMedCrossRef

Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32:273–84.PubMedCrossRef

Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297–301.PubMedCrossRef

Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44:1282–6.CrossRef

10.

Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26:1647–54.PubMedCrossRef

11.

Won Huh J, Soon Kim D, Keun Lee C, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med. 2007;101:1761–9.PubMedCrossRef

12.

Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59:677–85.PubMedCrossRef

13.

Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009;28(6):639–46.PubMedCrossRef

14.

Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005;32:58–64.PubMed

15.

Hayashi S, Tanaka M, Kobayashi H, et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol. 2008;35:260–9.PubMed

16.

• Yamasaki Y, Yamada H, Ohkubo M, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636–43. Erratum in: J Rheumatol 2011, 38:1815–1816. This retrospective study analyzed the long-term survival and associated risk factors of 197 IIM patients and suggested that ILD is the main cause of death in DM and C-ADM.PubMedCrossRef

17.

Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: characterization of the Jo-1 antibody system. Arthritis Rheum. 1980;23:881–8.PubMedCrossRef

18.

Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature. 1983;304:177–9.PubMedCrossRef

19.

Mathews MB, Reichlin M, Hughes GRV, et al. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med. 1984;160:420–34.PubMedCrossRef

20.

Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAala coexist and are associated with myositis. J Exp Med. 1986;163:1281–91.PubMedCrossRef

21.

Targoff IN, Trieu EP, Plotz PH, et al. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 1992;35:821–30.PubMedCrossRef

22.

Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993;91:2556–64.PubMedCrossRef

23.

Hirakata M, Suwa A, Nagai S, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol. 1999;162:2315–20.PubMed

24.

Betteridge Z, Gunawardena H, North J, et al. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford). 2007;46:1005–8.CrossRef

25.

Hashish L, Trieu EP, Sadanandan P, et al. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with anti-synthetase syndrome (abstract). Arthritis Rheum. 2005;52:S312.CrossRef

26.

Targoff IN. Immune manifestation of inflammatory muscle disease. Rheum Dis Clin North Am. 1994;20:857–80.PubMed

27.

Yoshida S, Akizuki M, Mimori T, et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983;26:604–11.PubMedCrossRef

28.

Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77:1019–38.PubMedCrossRef

29.

Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39:233–41.PubMedCrossRef

30.

Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007;34:1012–8.PubMed

31.

• Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60:2183–92. Ninety patients with anti-Jo-1 antibody were analyzed, and 86% of the cases were associated with ILD. A significant association between anti-Jo-1-positive ILD and elevated levels of interferon-γ-inducible chemokines CXCL9 and CXCL10 was revealed.PubMedCrossRef

32.

Hirakata M, Suwa A, Takada T, et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum. 2007;56:1295–303.PubMedCrossRef

33.

Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford). 2007;46:842–5.CrossRef

34.

• Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009;135:1550–6. A total of 31 patients with anti-PL-12 antibody were analyzed, and anti-PL-12 was strongly associated with the presence of ILD, but less so with myositis and arthritis.PubMedCrossRef

35.

Fischer A, Swigris JJ, du Bois RM, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103:1719–24.PubMedCrossRef

36.

Sato S, Hirakata M, Kuwana M, et al. Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol. 2005;23:609–15.PubMed

37.

• Koreeda Y, Higashimoto I, Yamamoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med. 2010;49:361–9. Clinicopathological characteristics of ILD in 14 patients with antisynthetase syndrome were reviewed. Chronic clinical course, lung-base GGO with volume loss, NSIP pattern, and good response to corticosteroids were the characteristic features.PubMedCrossRef

38.

Rutjes SA, Vree Egberts WT, Jongen P, et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 1997;109:32–40.PubMedCrossRef

39.

La Corte R, Lo Mo Naco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39:249–53.PubMedCrossRef

40.

Vancsa A, Csipo I, Nemeth J, et al. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int. 2009;29:989–94.PubMedCrossRef

41.

Katsumata Y, Ridgway WM, Oriss T, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007;29:174–86.PubMedCrossRef

42.

• Barbasso Helmers S, Englund P, Engström M, et al. Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum. 2009;60:2524–30. Erratum in: Arthritis Rheum 2009, 60:2746. Sera from PM-ILD with anti-Jo-1 antibody (but perhaps not with the antibody itself) showed a strong effect on the expression of ICAM-1 from endothelial cells from human lung.PubMedCrossRef

43.

Howard OM, Dong HF, Yang D, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196:781–91.PubMedCrossRef

44.

Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993;100:124S–7S.PubMedCrossRef

45.

Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626–36.PubMedCrossRef

46.

Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003;22:245–50.PubMedCrossRef

47.

Yokoyama T, Sakamoto T, Shida N, et al. Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes. J Intensive Care Med. 2005;20:160–3.PubMedCrossRef

48.

Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28:1005–12.PubMedCrossRef

49.

Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597–613.PubMedCrossRef

50.

Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136:1341–7.PubMedCrossRef

51.

Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.PubMedCrossRef

52.

•• Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49:433–40. In this article, the target autoantigen recognized by anti-CADM-140 antibody was identified as IFIH1/MDA5, and at first the association between anti-CADM-140-positive patients and hyperferritinemia was described.CrossRef

53.

• Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49:1726–33. Anti-CADM-140 (MDA5) and anti-TIF1-γ antibodies were detected by a new method immunoprecipitating with biotinylated recombinant MDA5 and TIF1-γ. A total of 26% and 65% were positive for anti-MDA5 in DM and C-ADM, respectively; 95% of the antibody-positive patients had ILD.CrossRef

54.

Kang EH, Nakashima R, Mimori T, et al. Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010;11(1):223.PubMedCrossRef

55.

Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25–34.PubMedCrossRef

56.

Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–8.PubMedCrossRef

57.

•• Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713–9. In this article, serum ferritin level was reported to be significantly high in the subset with anti-CADM-140 (MDA5) antibody, which correlates with disease activity and predicts prognosis.CrossRef

58.

Gono T, Kawaguchi Y, Sugiura T, et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford). 2010;49:1878–81.CrossRef

59.

•• Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193–200. This is an important article that first identified the target autoantigen recognized by anti-CADM-140 antibody to be MDA5.PubMedCrossRef

60.

Christensen ML, Pachman LM, Schneiderman R, et al. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 1986;29:1365–70.PubMedCrossRef

61.

Bowles NE, Dubowitz V, Sewry CA, et al. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet. 1987;1:1004–7.PubMedCrossRef

62.

Chevrel G, Calvet A, Belin V, et al. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford). 2000;39:1037–9.CrossRef

63.

Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182–5.PubMed

64.

Kalluri M, Oddis CV. Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med. 2010;31:501–12.PubMedCrossRef

65.

Daimon T, Johkoh T, Honda O, et al. Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types. Intern Med. 2009;48:753–61.PubMedCrossRef

66.

Mino M, Noma S, Taguchi Y, et al. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol. 1997;169:83–7.PubMed

67.

• Watanabe K, Handa T, Tanizawa K, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011;105:1238–47. Antisynthetase antibodies were detected in 13 patients (6.6%) from 198 with idiopathic interstitial pneumonia. On HRCT, GGO and traction bronchiectasis were the major findings in these patients.PubMedCrossRef

68.

•• Tanizawa K, Handa T, Nakashima R, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Resp Med. 2011;105:1380–7. HRCT pattern of anti-CADM-140-positive ILD was described. Lower consolidation or GGO pattern and random GGO pattern, but the absence of intralobular reticular opacities, were the characteristic HRCT findings in these patients.CrossRef

69.

Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis. 2000;59:257–62.PubMedCrossRef

70.

Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000;39:632–6.CrossRef

71.

Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378–81.PubMed

72.

Satoh H, Kurishima K, Ishikawa H, et al. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006;260:429–34.PubMedCrossRef

73.

Kumánovics G, Minier T, Radics J, Pálinkás L, et al. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol. 2008;26:414–20.PubMed

74.

Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2011;Sep 23. [Epub ahead of print].

75.

• Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1354–60. Significantly high levels of serum ferritin were observed in DM patients with acute or subacute ILD, and patients with ferritin levels higher than 1,500 ng/mL showed poor prognosis.CrossRef

76.

Gono T, Kawaguchi Y, Ozeki E, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 2011;21:223–7.PubMedCrossRef

77.

Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56:3125–31.PubMedCrossRef

78.

Sato S, Kuwana M, Fujita T, et al. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 2011;Nov 29. [Epub ahead of print].

79.

Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol. 1999;26:1527–33.PubMed

80.

Shinohara T, Hidaka T, Matsuki Y, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med. 1997;36:519–23.PubMedCrossRef

81.

Yoshida T, Koga H, Saitoh F, et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med. 1999;38:733–8.PubMedCrossRef

82.

Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46:124–30.CrossRef

83.

Tanaka F, Origuchi T, Migita K, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med. 2000;39:428–30.PubMedCrossRef

84.

Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719–26.PubMed

85.

Maeda K, Kimura R, Komuta K, et al. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol. 1997;26:24–9.PubMedCrossRef

86.

Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38:383–92.PubMedCrossRef

87.

Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2008;35:254–9.PubMed

88.

• Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. 2011;30:1021–8. The efficacy of a combination with corticosteroids and CSP was reported in 14 DM patients with acute or subacute ILD.PubMedCrossRef

89.

• Nagai K, Takeuchi T, Kotani T, et al. Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis. Mod Rheumatol. 2011;21:32–6. CSP blood level, especially C0 and C2, is useful to monitor clinical and adverse effects of CSP, and once-daily preprandial administration is beneficial in DM patients with progressive ILD.PubMedCrossRef

90.

Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2005;23:707–10.PubMed

91.

Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762–3.PubMedCrossRef

92.

Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439–46.PubMedCrossRef

93.

• Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48:968–71. Eleven refractory ILD patients with antisynthetase syndrome were treated with rituximab, and 7 of 11 showed a short-term beneficial effect on ILD.CrossRef

94.

Vandenbroucke E, Grutters JC, Altenburg J, et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int. 2009;29:1499–502.PubMedCrossRef

95.

Ball EM, Savage EM, Pendleton A. Refractory anti-synthetase syndrome treated with rituximab. Rheumatology (Oxford). 2010;49:1013.CrossRef

96.

• Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337:329–35. MMF was administered to 10 patients with autoimmune-related ILD (including 2 PM), and all patients showed stabilization and/or improvement of the disease.PubMedCrossRef

97.

• Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken). 2010;62:496–501. Three of four patients with DM-ILD who received MMF experienced improvement in pulmonary function and dyspnea and reduction of corticosteroid doses.CrossRef

98.

Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187:201–6.PubMedCrossRef

99.

Dasrmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670–7.CrossRef

100.

The Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427–36.CrossRef

101.

Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011;50:1344–6.CrossRef

102.

Furlan A, Botsios C, Ruffatti A, et al. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine. 2008;75:366–7.PubMedCrossRef

Titel: Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment
verfasst von: Tsuneyo Mimori
Ran Nakashima
Yuji Hosono
Publikationsdatum: 01.06.2012
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 3/2012
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-012-0246-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Disentangling the Emerging Evidence around Atypical Fractures

Erratum to: An Update on the Evaluation and Management of Pulmonary Hypertension in Scleroderma

Endoplasmic Reticulum Stress in Skeletal Muscle Homeostasis and Disease

Animal Models of Inflammatory Myopathy

Bone Loss in Rheumatoid Arthritis: Systemic, Periarticular, and Focal

From Fracture Risk Prediction to Evaluating Fracture Patterns: Recent Advances in the Epidemiology of Osteoporosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin